See more here:
Windtree Announces Istaroxime Presentation By Cardiogenic Shock Thought Leader At Cardiovascular Clinical Trials Conference
Related Post
- Crinetics Pharmaceuticals Appoints Isabel Kalofonos as Chief Commercial Officer - December 17th, 2024
- Upstream Bio Announces Addition to Russell 2000® Index - December 17th, 2024
- FibroGen Appoints David DeLucia as Chief Financial Officer - December 17th, 2024
- Catalyst Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference - December 17th, 2024
- Oragenics, Inc. Announces Conversion of Preferred Shares and Elimination of Liquidation Preference - December 17th, 2024
- Allogene Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - December 17th, 2024
- Wave Life Sciences to Present at 43rd Annual J.P. Morgan Healthcare Conference - December 17th, 2024
- Clearmind Medicine and Dr Glitter Pty Ltd Sign Term Sheet for Mutual Development of Novel Psychedelic MEAI- Based Alcohol Substitute in... - December 17th, 2024
- New InsiGHTS Trial of TransCon™ hGH (Lonapegsomatropin) in Turner Syndrome Achieved Primary Objective at Week 26 - December 17th, 2024
- invIOs to present progress across oncology pipeline during JP Morgan Week 2025 - December 17th, 2024
- Akari Therapeutics Appoints Torsten Hombeck, Ph.D. as Chief Financial Officer - December 17th, 2024
- Scilex Holding Company Announces Early Installment Payment on its Senior Secured Promissory Note, Paving the Way for Future Growth and Innovation - December 17th, 2024
- Cannara Provides Update on Its 2024 Annual General Meeting Materials amid Canada Post Strike - December 17th, 2024
- Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL Amyloidosis - December 17th, 2024
- Enzo Biochem Reports First Quarter Fiscal Year 2025 Results and Provides a Company Update - December 17th, 2024
- Bionomics Announces Supreme Court of New South Wales Approves Bionomics’ Re-Domiciliation - December 17th, 2024
- Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertrophic... - December 17th, 2024
- Regeneron Named to Dow Jones Sustainability World Index for Sixth Consecutive Year - December 17th, 2024
- Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D) - December 17th, 2024
- Biomea Fusion Announces Oral and Poster Presentations of Icovamenib at the 22nd World Congress on Insulin Resistance, Diabetes & Cardiovascular... - December 15th, 2024
- HUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA® (fruquintinib) - December 15th, 2024
- LakeShore Biopharma Provides Update on Ongoing Criminal Investigation Involving Former Chairman in China - December 15th, 2024
- Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl) - December 15th, 2024
- Rakovina Therapeutics Announces Closing of Oversubscribed $3M Private Placement - December 15th, 2024
- Kellner Group Denounces False Rumors About AIM Short Selling and Demands Immediate Accountability from Incumbent Board - December 15th, 2024
- Novo Nordisk A/S: The acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites from Novo... - December 15th, 2024
- Pharming announces public cash offer to the shareholders of Abliva AB - December 15th, 2024
- Press Release: Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosis - December 13th, 2024
- Roche receives CE Mark for new and updated molecular cobas 6800/8800 systems, enhancing laboratory efficiency and testing capabilities - December 13th, 2024
- Actimed Therapeutics Announces Publication of Successful S-pindolol benzoate (ACM-001.1) Phase 1 Study in The Journal of Cachexia, Sarcopenia and... - December 13th, 2024
- Roche’s Vabysmo prefilled syringe (PFS) approved in the EU for three retinal conditions that can cause blindness - December 13th, 2024
- ITM to Present at the 43rd Annual J.P. Morgan Healthcare Conference - December 13th, 2024
- Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors - December 13th, 2024
- Polyrizon Announces Appointment of VP of Regulatory Affairs and Quality Assurance - December 13th, 2024
- Genelux Corporation to Participate in a Fireside Chat with H.C. Wainwright - December 13th, 2024
- Incyclix Bio Announces Interim Clinical Data from the Phase 1/2 Clinical Trial of INX-315 in Patients with CDK4/6 Inhibitor Resistant ER+/HER2- Breast... - December 13th, 2024
- Acoramidis Receives Positive CHMP Opinion for Treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM) - December 13th, 2024
- Assertio Announces Results of Rolvedon® (eflapegrastim-xnst) injection Same-Day Dosing Clinical Study - December 13th, 2024
- Medicenna Presents Preclinical Data on MDNA11 as First Step to Shrink Tumors Before Surgery and Prevent Metastasis at the 2024 San Antonio Breast... - December 13th, 2024
- Amarin Appoints Peter Fishman Chief Financial Officer - December 13th, 2024
- SPR® Therapeutics Recognized as the Fastest Growing Private Company in Northeast Ohio as Part of the Crain’s Fast 50 List - December 13th, 2024
- Spectral AI Comments on Compliance with Nasdaq Listing Rule 5550(b)(2) - December 13th, 2024
- Kellner Group Urges Stockholders of AIM Immunotech to Vote Gold Card - December 13th, 2024
- UPDATE: Kellner Group Urges Stockholders of AIM Immunotech to Vote Gold Card - December 13th, 2024
- CannExpo 2025: Igniting the Cannabis Lifestyle in Toronto - December 13th, 2024
- Outlook Therapeutics® Streamlines Operations - December 13th, 2024
- Edesa Biotech Reports Fiscal Year 2024 Results - December 13th, 2024
- Kraig Biocraft Laboratories Reports Record-Setting Recombinant Spider Silk Production in 2024 - December 11th, 2024
- Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit - December 11th, 2024
- Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in... - December 11th, 2024
- AIM’s Clinical Strategy Under Incumbent Board Has Totally Failed - December 11th, 2024
- Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company, Reports Phase 2 Trial for Obesity Currently Enrolling with U.S. Patient... - December 11th, 2024
- Reunion Neuroscience Presented RE104 Phase 1 Data at the 2024 American College of Neuropsychopharmacology (ACNP) 63rd Annual Meeting - December 11th, 2024
- RenovoRx Initiates Patient Enrollment at SCRI Oncology Partners for Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial in Locally Advanced Pancreatic... - December 11th, 2024
- Results from Social Listening Analysis and Survey of People with Narcolepsy Uncover Real-Life Challenges with Twice-Nightly Oxybate Therapy - December 11th, 2024
- Teva Announces New Patient Access Program with Direct Relief to Provide Access to Inhalers for Uninsured Patients - December 11th, 2024
- Hepion Pharmaceuticals, Inc. Announces Termination of Merger Agreement with Pharma Two B Ltd. - December 11th, 2024
- Phathom Pharmaceuticals Submits Citizen Petition to FDA Seeking Correction of Orange Book Listings for VOQUEZNA® (vonoprazan) Tablets - December 11th, 2024
- Angitia Biopharmaceuticals Announces $120 Million Series C Financing - December 11th, 2024
- Genmab to Hold 2024 R&D Update and ASH Data Review Meeting - December 11th, 2024
- Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis - December 11th, 2024
- Aprea Therapeutics Announces Twice Daily (BID) Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potentially Optimize Clinical Outcomes... - December 11th, 2024
- Enlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis - December 11th, 2024
- New Clinical Trial of eTNS for Pediatric ADHD to Commence at Denmark’s Center for Evidence-Based Psychiatry - December 11th, 2024
- 60 Degrees Pharmaceuticals Expands Tafenoquine Clinical Trial for Babesiosis to Brigham and Women’s Hospital - December 11th, 2024
- Phenocell and Amarna Therapeutics Awarded Eurostars Grant to Assess a Gene Therapy for Dry AMD using a novel 3-dimensional iPSC-derived Retinal Model... - December 11th, 2024
- NurExone Announces Promising Preclinical Results in Restoring Vision After Optic Nerve Damage - December 9th, 2024
- BioAge Labs Announces Discontinuation of STRIDES Phase 2 Clinical Trial Evaluating Azelaprag in Combination with Tirzepatide for the Treatment of... - December 9th, 2024
- Press Release: ASH: rilzabrutinib demonstrated significant patient benefit in the first positive phase 3 study of a BTK inhibitor in ITP - December 9th, 2024
- Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association’s... - December 9th, 2024
- Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory... - December 9th, 2024
- Y-mAbs Presents SADA Platform Preclinical Data and Trial in Progress Posters at the 2024 American Society Hematology (ASH) Annual Meeting - December 9th, 2024
- Novel Combination of Pozelimab and Cemdisiran (Poze-Cemdi) Achieved Greater Control of Intravascular Hemolysis in Patients with Paroxysmal Nocturnal... - December 9th, 2024
- Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ® and Its Impact on... - December 9th, 2024
- Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With... - December 9th, 2024
- Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or... - December 9th, 2024
- Affimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK® Combination in Relapsed/Refractory Classical Hodgkin... - December 9th, 2024
- DARZALEX® (daratumumab) subcutaneous formulation shows 51 percent reduction in risk of progression to active multiple myeloma for patients with... - December 9th, 2024
- C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become... - December 9th, 2024
- Cogent Biosciences Announces Positive Updated Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic... - December 9th, 2024
Recent Comments